Elexacaftor/Tezacaftor/Ivacaftor and Neuropsychiatric Symptoms: Nonclinical and Clinical Studies

Fredrick Van Goor[1], Laurent Francioli [1], Patrick R. Sosnay [1], James L. Kreindler [1], Neil Ahluwalia [1], Mark J. Daly[2], Weichao Chen [1], David Altshuler [1]

[1] Vertex Pharmaceuticals Incorporated, Boston, MA, USA;[2] Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Abstract

Rationale: Cystic fibrosis (CF) is a chronic, life-limiting genetic disease. CFTR modulators such as elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) have significantly improved clinical outcomes and quality of life for many people with CF. While most individuals report no change or improvement in neuropsychiatric symptoms with ELX/TEZ/IVA, a minority experience new or worsening symptoms.

Objectives: Assess whether neuropsychiatric symptoms are an off-target or on-target pharmacological effect of ELX/TEZ/IVA.

Methods: To evaluate potential off-target or on-target effects of ELX/TEZ/IVA on neuropsychiatric symptoms we conducted: (a) in vitro off-target screening at clinically relevant concentrations; (b) non-clinical, in vivo behavioral pharmacology studies; (c) analysis of clinical trial and real-world data for evidence of neuropsychiatric adverse events; and (d) human genetic analysis of ~1M individuals with neuropsychiatric disorders to assess for potential associations with *CFTR* functional variants.

Measurements and Main Results: No off-target effects of ELX, TEZ, or IVA were observed in vitro or in vivo animal studies at clinically relevant free concentrations. Clinical trial and real-world data covering >52,000 patient-years of experience with ELX/TEZ/IVA showed no increase in risk of neuropsychiatric adverse events. Human genetic analyses of functional *CFTR* variants did not show association with any of 23 neuropsychiatric conditions.

Conclusions: Multiple independent lines of investigation failed to show any evidence for off-target or on-target effects of CFTR modulators, CFTR human genetic variants and neuropsychiatric symptoms.

Keywords: CFTR modulators, neuropsychiatric, cystic fibrosis

Introduction

Cystic fibrosis (CF) is a chronic, life-limiting genetic disease that is progressive from birth, leading to multi-organ damage and early death.(1) As with other serious chronic diseases, people with CF (pwCF) have increased risk for adverse psychological symptoms – including higher rates of depression and anxiety – as compared to healthy peers.(2, 3) Prior to the widespread introduction of CFTR modulators, data from a 2014 study in 6,088 pwCF across 9 countries showed symptoms of depression in 5 to 19% of adolescents and 13 to 29% of adults; symptoms of anxiety were observed in 22% of adolescents and 32% of adults with CF.(3)

CFTR modulator therapies that directly treat the underlying cause of CF have altered the disease trajectory for many pwCF.(4) The triple combination of elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) has been shown to improve lung function and quality of life, reduce pulmonary exacerbations, hospitalizations and lung transplants, and to potentially significantly extend life expectancy, especially when initiated early in life.(5)

Clinical trial and real-world evidence document that most pwCF treated with ELX/TEZ/IVA experience either no change or an improvement in mental and/or emotional well-being.(6) However, a minority of people treated with ELX/TEZ/IVA report new or worsening psychological symptoms, including depression, anxiety, sleep disturbance, and cognitive changes, such as brain fog.(7, 8) These symptoms typically occur within the first three months of treatment and, in some cases, have led to treatment interruptions or discontinuations.(7)

A central question about these adverse neuropsychiatric effects is to determine if they are either an off-target or on-target pharmacological effect of ELX/TEZ/IVA. Some published studies have used in vitro experiments with free (unbound) concentrations of ELX, TEZ, or IVA that far

exceed clinically relevant exposures, leading to the hypothesis that ELX, TEZ, or IVA may exert off-target effects on central nervous system receptors associated with neuropsychiatric symptoms.(9, 10) Alternatively, it has been proposed that on-target effects on CFTR expressed in the brain could potentially contribute to mood and cognitive changes.(10, 11)

To evaluate these hypotheses, we examined: 1) in vitro off-target binding activity in a broad panel of neuropsychiatric targets at clinically relevant free concentrations of ELX, TEZ, and IVA, assessed changes in neurobehavioral endpoints in rats following oral administration of ELX, TEZ, or IVA, and searched for association between CFTR and neuropsychiatric observations across clinical trials and real-world evidence studies. We also analyzed human genetic data from ~1 million people from international neuropsychiatric genetic disease studies to determine whether functional *CFTR* variants have an association with neuropsychiatric diseases. Collectively, these studies failed to identify evidence of either off-target or on-target effects of CFTR modulators on neuropsychiatric traits.

Methods

Receptor binding assays

Off-target binding activity of CFTR modulators was tested using the LeadProfilingScreen and/or SpectrumScreen® Panel methods (https://www.eurofinsdiscovery.com [Accessed September 2025]) on a comprehensive panel of neuropsychiatric targets.

Rat neurobehavioral studies

Sprague Dawley rats were randomly assigned to receive ELX, TEZ, or IVA by oral gavage at three dose levels, with vehicle controls included in all studies and a positive control (chlorpromazine) in the IVA study. Neurobehavioral effects were assessed using the Irwin test

(IVA) or Functional Observational Battery (FOB; ELX and TEZ) at multiple time points post-dose to capture peak plasma concentrations (C_{max}).(12, 13) Parameters evaluated included activity, autonomic function, neuromuscular and sensorimotor responses, and general health (**Table E1**). Data were compared between treated and control groups to identify any neurobehavioral changes, with statistical analysis performed for FOB endpoints. Detailed methods and analysis are provided in the Appendix.

Determination of the free concentration at the C_{max} for ELX, TEZ, and IVA

Free concentrations of ELX, TEZ, and IVA at the C_{max} were determined by multiplying total C_{max} by the free fraction (unbound) as determined using the equilibrium dialysis method (see Appendix). Standard noncompartmental analyses were used to determine pharmacokinetic (PK) parameters such as $C_{max.}$ Population PK methods were used to characterize exposures of ELX, TEZ, and IVA in healthy subjects and CF subjects incorporating the effects of demographic characteristics and other covariates on PK.

Rat brain distribution studies

The tissue distribution of CFTR modulators was determined by administering radiolabeled ^{14}C to male Sprague-Dawley rats and measuring tissue specific levels at various timepoints postdosing (see Appendix).

Pooled CFTR modulators clinical trials

Relevant psychiatric events from the pivotal, placebo-controlled studies and open-label extensions of ELX/TEZ/IVA, TEZ/IVA, LUM/IVA, and IVA modulators were identified by preferred term. Additionally, relevant events from over 60 Phase 2 and 3, controlled and uncontrolled clinical trials in all 4 modulators (IVA, LUM/IVA, TEZ/IVA, ELX/TEZ/IVA) were

identified and pooled. The data are summarized for events, serious events, and events leading to treatment discontinuation.

Real-world outcomes from US and German CF registries

Prevalence of depression and anxiety diagnosis in pwCF treated with ELX/TEZ/IVA was assessed using United States (US) and German CF registries as part of an ongoing post-approval safety study. Data from 8,967 US and 1,028 German patients who started ELX/TEZ/IVA between late 2019 and 2021 and had non-missing data in all years were analyzed, comparing prevalence over 4 years post-treatment to the 5 years prior.

Systematic Review of Published Literature

A systematic literature review (SLR) was conducted to evaluate observational studies assessing neuropsychiatric outcomes before and after ELX/TEZ/IVA initiation (**Figure E1**). The SLR adhered to established methods for conducting systematic reviews and were reported in accordance with the Preferred Reporting Items for Systematic Literature Reviews and Meta-Analyses (PRISMA) statement. (14)

Genetic studies

To assess whether CFTR modulation in the brain is associated with neuropsychiatric traits we analyzed the common CF-causing *F508del*-CFTR variant as well as that of rare, severe CFTR protein-truncating variants (Class I variants).

First, we evaluated association data in a broad and unbiased set of phenotypes using publicly available data from multiple biobanks. For *F508del*-CFTR associations, we used data from the UKBB/FinnGen browser (https://metaresults-ukbb.finngen.fi/gene/CFTR) that provides meta-

analysis of genome-wide associations studies (GWAS) results from two large biobanks (UK Biobank and FinnGen) encompassing 873 phenotypes in approximately 1 million individuals. For CFTR protein-truncating variants, we used burden tests associations from Genebass (https://app.genebass.org/) spanning 4,529 phenotypes across 394,841 individuals from the UK biobank, and All by all (https://allbyall.researchallofus.org/) encompassing ~3,400 traits across ~250,000 individuals from the All of Us biobank. We searched for potential associations across all phenotypes. The pre-specified threshold for genome-wide association is 10^{-8}; threshold for suggestive association in a phenome-wide scan is $p < 10^{-4}$ for exome sequencing, and $< 10^{-5}$ for genome wide association data.

We then examined associations of the same variants in ~1M human DNA samples spanning 23 diagnosed neuropsychiatric diseases and mental health traits using the same analytic approaches. For *F508del*-CFTR, we used GWAS summary statistics from 21 studies. When *F508del-CFTR* was not included in the study, we used the closely linked rs113827944 variant ($r^2 = 0.7$ in Europeans) as a proxy. For CFTR protein-truncating (Class 1) variants, we used burden tests from whole-exome sequencing for 3 neuropsychiatric disease available through public browsers: autism spectrum disorder (ASC, https://asc.broadinstitute.org/gene/ENSG00000001626), bipolar disorder (BipEx, https://bipex.broadinstitute.org/gene/ENSG00000001626 and schizophrenia (SCHEMA, https://schema.broadinstitute.org/gene/ENSG00000001626) . In addition, we used data from Tian et al.(15) on depression and we. curated a set of 12 diagnosed neuropsychiatric or mental health conditions with large number of cases from Genebass and All by All. The pre-specified threshold for genome-wide association is 10^{-8}; based on 46 hypothesis tests (F508del and protein-truncating variants each for 23 neuropsychiatric diseases) the threshold for suggestive association is $p < 10^{3}$.

Results

Receptor binding studies did not identify any clinically relevant off-target activity for ELX, TEZ, or IVA

No clinically relevant off-target binding activity was observed for ELX, TEZ, or IVA across more than 65 neuropsychiatric-related receptors, ion channels, and transporters (**Table 1**). The pharmacologically relevant in vivo concentration of a small molecule medicine is the free (unbound) concentration that is able to interact with the target, since protein-bound small molecules are not pharmacologically active.(15) There is high human plasma protein binding of ELX (99.3%), TEZ (99.1%), and IVA (99.95%) that means the free concentration of each is a small fraction of the total concentration. Thus, in vitro assays (performed in the absence of serum protein) must be compared to the clinically relevant free drug concentration, not the total plasma protein concentration.(16) For all targets tested, there is a large margin between the free concentration in vitro and the free concentration in the plasma at the therapeutically relevant C_{max} for ELX, TEZ, and IVA (**Table 1**).

To evaluate the relative concentrations for ELX, TEZ, and IVA in the brain as compared to plasma we used rat ^{14}C radiolabel tissue distribution studies. These studies showed that at C_{max} the brain concentrations of ELX, TEZ and IVA were approximately 23%, 39%, and 3% of the concentration measured in plasma, respectively (**Table 2**). The reduced exposure in the non-clinical CNS distribution study, combined with the high protein binding of the CFTR modulators, indicates the free drug concentrations in the CNS may be even lower than those in the in vitro assays. This potentially provides a larger margin between any off-target activity in vitro and the clinically relevant free concentration in the CNS.

Animal neurobehavioral studies in rats did not identify central nervous system pharmacological activity following oral administration of ELX, TEZ, or IVA

No neurobehavioral changes were observed in rats treated with ELX, TEZ, or IVA across all dose groups and time points (**Table 3**). In the Irwin test, rats administered IVA showed no deviation from normal across all evaluated parameters at any dose or post dose time point. To confirm assay sensitivity, chlorpromazine-treated rats served as a positive control and exhibited the expected signs of central nervous system depressant activity, including decreased body tone, decreased touch response, ptosis, and abnormal gait. Similarly, rats treated with TEZ or ELX demonstrated normal results across all FOB endpoints (activity/arousal, autonomic, neuromuscular, sensorimotor, and physiological) and were comparable to controls. No mortality or adverse clinical observations were reported for any CFTR modulator group. Collectively, these findings indicate that neither IVA (Irwin test) nor TEZ or ELX (FOB) induced neurobehavioral effects in rats, supporting the absence of direct central nervous system activity.

Clinical trial and real-world data do not suggest an association between CFTR modulators and neuropsychiatric symptoms

To evaluate whether CFTR modulators affect neuropsychiatric symptoms, we analyzed data from clinical trials, real-world studies, and a literature review.

Clinical Trial Experience: Analysis of clinical trials with nearly 6,000 participants and over 12,000 patient-years (PY) of exposure showed no evidence linking CFTR modulator treatment and neuropsychiatric events. Rates of neuropsychiatric symptoms were low and similar between both treatment and placebo groups in Phase 3 studies and their open-label extensions (**Table 4**). The nature of the neuropsychiatric events was similar across both treatment and placebo groups

in these studies (**Table E3**). Across 60 Phase 2 and 3 trials, the incidence and nature of the neuropsychiatric events were comparable between treated and placebo groups (**Table E4**). Notably, the rate of neuropsychiatric events in study participants treated with CFTR modulators was lower (6.9 events/100 PY) for all modulators than in the pooled placebo group (9.6 events/100 PY). Serious neuropsychiatric events and those leading to treatment discontinuation were infrequent and occurred at similar rates between the treated and placebo groups.

Post-authorization Safety Studies: A registry-based safety study sponsored by Vertex found that observed temporal patterns of depression or anxiety diagnoses prevalence did not change following the initiation of ELX/TEZ/IVA (**Figure 1**).

Literature search for CFTR modulator and depression- or anxiety-related events: A systematic literature review (SLR) identified 21 real world data publications from 8 countries (>1,300 patients) that systematically assessed depression (12 studies), anxiety (11 studies), sleep quality/disturbances (6 studies), and other topics (behavioral issues, emotional quality of life: 12 studies) using instruments such as the PHQ-9, GAD-7, and others (**Figure E1**). Key results are summarized in **Table E5**.

No study identified significant worsening of mental health outcomes at the population level following ELX/TEZ/IVA initiation (**Table E5**). Of 12 studies evaluating depression scores following initiation of ELX/TEZ/IVA treatment, 8 studies reported no change, 3 reported improvements, and one reported a mixed result depending on the instrument used. Among 11 studies evaluating anxiety, 9 found no change and 2 reported improvements. Sleep quality was assessed in 6 studies, with 3 showing no change and 2 showing improvement; an additional study using polysomnography found either no change or improvement across sleep indices. Emotional quality of life and behavioral outcomes also showed no change or improvement following CFTR

modulator ELX/TEZ/IVA initiation. One of these studies evaluated behavioral patterns in children using the PSC-17 instrument and showed no change following ELX/TEZ/IVA initiation.

No human genetic association between CFTR variants and a broad spectrum of neuropsychiatric diseases in approximately 1M individuals

One hypothesis that has been proposed is that CFTR expression and function in the CNS could possibly be related to neuropsychiatric traits, such that CFTR modulators could have on-target effect on such traits. To evaluate this possibility, we analyzed human genetic data from 24 studies and 3 biobanks to evaluate any phenotypic effects of CFTR variants in approximately 1 million individuals with one or more of 23 diagnosed neuropsychiatric or mental health diagnoses (**Figure 2; Tables E6a, E6b**). By the principle of Mendelian Randomization(17), inherited genetic variants affecting the function of a gene provide an unconfounded assessment of the relationship between function and outcome, thereby testing the hypothesis that alterations in CFTR function have a direct effect on a phenotype of interest.

The human genetic analysis involved two distinct and complementary analyses of CFTR functional variants. One used genotype of the common variant *F508del-CFTR*; the other used pooled protein-truncating variants in CFTR from exome sequencing data. To evaluate whether these CFTR functional variants have association with any human traits we first performed phenome-wide scans in public biobanks data using standard guidelines for human genetic analysis (See methods, **Figure 2**, **Table E6a**). For *F508del-CFTR* we analyzed a meta-analysis of two large public biobanks including approximately 1 million individuals and 873 phenotypes. For the CFTR protein-truncating variants analysis, we used data from two biobanks totaling 645,000 individuals and 1,195 phenotypes.

Results from these analyses in two large public biobanks meeting the criteria above showed that *F508del* was associated with an increased risk of aspergillosis (beta = 1.05, p = 7.41e-8) and chronic pancreatitis (beta = 0.588, p = 3.43e-7) and that pooled Class I CFTR protein-truncating variants were associated with Staphylococcus infections (beta = 4.83, p = 1.35e-6), mucolytics (beta = 4.32, p = 1.55e-5), drug resistant microorganisms (beta = 4.17, p = 3.04e-5), vitamin K (beta = 4.10, p = 4.14e-5), bronchiectasis (beta = 3.90, p = 9.64e-5) and pneumonia (beta = 4.09, p = 4.33e-5). The fact that unbiased phenome scanning of CF-causing CFTR variants identified only established CF-related phenotypes supports the sensitivity and validity of this approach.

We next performed the same association methods (*F508del* and pooled CFTR protein-truncating variants) across 20 genome-wide association and 4 exome sequencing studies of diagnosed patients and controls for 23 neuropsychiatric or mental health diagnoses (**Figure 2, Table E6b**). These studies are by consortia that have successfully discovered genetic variants associated with each neuropsychiatric condition and in total include ~1 million cases of one or more psychiatric diseases. The different studies span sample sizes from 10,000 to >1 million participants, with case counts ranging from 660 to 191,800, diagnosed patients. For the pooled CFTR protein-truncating variants, we also used 12 curated phenotypes from the two biobanks as described above because sequencing data from disease cohorts were not available.

Results of the analysis of *F508del-CFTR* and of protein-truncating (Class 1) CFTR variants identified no associations that met the pre-specified statistical threshold for any of the neuropsychiatric or mental health traits.

In addition, we used public data from the Genotype-Tissue Expression (GTEX; https://www.gtexportal.org/home/snp/rs10255092, consulted Sep. 19th, 2025) to identify a common non-CF-causing variant (rs10255092) upstream of CFTR that is associated with

expression of CFTR mRNA in the CNS. Association studies of this variant that modifies CFTR expression in the CNS showed no association with any of the 23 neuropsychiatric or mental health traits investigated (**Table E6b**).

Taken together, these human genetic studies identified associations of CFTR variants to traits known to be associated with CFTR function and expression but did not identify any association of CFTR variants with neuropsychiatric traits. Thus, they fail to support the hypothesis that changes in function of CFTR in the brain are associated with changes in psychiatric, cognitive, or neurological traits.

Discussion

A central question of current care for pwCF is whether reported neuropsychiatric symptoms in a subset of individuals treated with ELX/TEZ/IVA could be due to off-target or on-target pharmacology. To address this question, we conducted a comprehensive assessment of *in vitro* receptor binding studies, *in vivo* animal behavioral pharmacology studies, clinical trial and real-world data, and human genetic data in ~1 million individuals diagnosed with one or more neuropsychiatric diseases. We did not find any evidence of in vitro evidence of off-target effects at clinically relevant concentrations, of central nervous system behavioral changes in rats, of treatment with ELX/TEZ/IVA in clinical trials or real-world evidence, and of genetic evidence linking CFTR functional mutations to a broad spectrum of mental health disorders. The totality of the data fails to support the hypothesis that CFTR modulators directly exert an on-target or off-target effect on neuropsychiatric traits.

To interpret *in vitro* findings it is necessary to address the free drug concentrations in the plasma.(18) For example, at the C_{max} for 150 mg bid IVA when administered in combination with

ELX and TEZ, the total and free plasma concentrations of IVA are 3.057 µM and ~0.0014 µM, respectively. In the receptor binding assay (performed without serum protein), the IC_{50} for IVA against a broad spectrum of neuropsychiatric-related targets ranged from 0.85 µM to >10 µM. This indicated that there is a ~600-to->7100-fold margin between the in vitro IC_{50} and the clinically relevant free plasma concentration for IVA. Similar comparison can be made for published work. For example, the effects of ELX on large-conductance calcium channels were tested at 10 µM in the absence of serum protein,(10) a more than ~100-fold increase above the expected free concentration in vivo. Similarly, Scheider et al.(9) reported binding of IVA, M1-IVA and M6-IVA to 5-HT_2 receptors with a K_i = 0.866 µM, which is ~600 fold higher than the clinically relevant free concentration. Therefore, the in vitro activity previously reported using in vitro assays that lack serum protein would not be expected to result in meaningful activity in people due to the high protein binding of ELX, TEZ, and IVA.

In addition to the high protein binding of CFTR modulators, on-target and off-target activity in the brain may be further limited by the low predicted brain exposures of ELX, TEZ, and IVA relative to plasma concentrations. In rat tissue distribution studies, brain exposures of ELX, TEZ, and IVA were approximately 23%, 39%, and 3% of plasma exposures, respectively. These low brain concentrations are likely due to ELX, TEZ, and IVA being sensitive substrates of the P-glycoprotein (P-gp) efflux transporter, which is highly expressed at the blood-brain barrier and can actively pump these compounds out of the brain. While it is well accepted that P-gp substrates exhibit limited brain penetration, it is important to consider that P-gp expression is higher in rats than in humans. As a result, the low brain-to-plasma ratios in the rat may underestimate human brain exposures.

Although CFTR is expressed at low levels in the brain, its impact on mental health is unclear and confounded by the psychological burden of living with a serious chronic disease.(7) Some have hypothesized that increased CFTR function due to CFTR modulators may result in an on-target effect in the brain.(11) If this were true, a protective association between deleterious *CFTR* variants and neuropsychiatric disorders could be expected. To assess the potential biological role of CFTR in neuropsychiatric behavior, we therefore examined associations between *CFTR* variants and a broad spectrum of phenotypes, including 23 neuropsychiatric or mental health diagnoses, in ~ 1 million individuals. Consistent with prior studies, *CFTR* variants were associated with pancreatitis, aspergillosis, and bronchiectasis.(19) In contrast, no causal or protective associations were identified between *CFTR* variants and a broad spectrum of mental health diagnoses, including depression, anxiety, and cognitive impairment. Taken together, these genetic data and the uncertainty regarding the biological role of CFTR expression in the brain do not support the hypothesis that on-target activity leads to new or worsening neuropsychiatric symptoms.

Given the lack of evidence reported in this study for off-target or on-target effect of CFTR modulators on neuropsychiatric disease, it is appropriate to consider alternative hypotheses for the reported neuropsychiatric symptoms in some individuals with CF. One possibility is a secondary effect of changes in physical health and life expectancy on personal identity and needs. Transformative therapies in other serious diseases, such as antiretroviral treatment for HIV, organ transplantation, and cancer have significantly improved the quality and duration of life, but they may also trigger new or worsening neuropsychiatric symptoms. (20-22) Similar phenomenon could contribute to some of what is occurring with CFTR modulators. (23, 24).

This study has important limitations that warrant consideration. While clinical trial and registry data encompass large populations and extensive patient-years, detailed neuropsychiatric assessments were not systematically included in multi-center trials, making it challenging to detect rare or subtle effects. Smaller studies using validated instruments have not identified significant associations, but these are often unblinded and uncontrolled. Importantly, the absence of direct symptom queries in large datasets may reduce ascertainment bias, yet it also limits the ability to capture nuanced patient experiences. As such, while population-level analyses do not support a direct link between CFTR modulators and neuropsychiatric symptoms and anecdotal cases are often confounded by incomplete data and the fluctuating nature of neuropsychiatric symptoms, rare individual cases cannot be fully excluded. Additionally, not every potential neuropsychiatric target or disorder was examined in these analyses, leaving the possibility that effects on unstudied conditions may not have been detected.

In conclusion, a combination of *in vitro* and preclinical in vivo studies, clinical trial and real-world results, and human genetic data did not identify any evidence of a direct link between ELX/TEZ/IVA and off-target binding at clinically relevant concentrations, behavioral symptoms in animals, mental health symptoms in clinical trials, or association of CFTR functional variants with neuropsychiatric traits.

Acknowledgments

The authors thank the patients and their families for participating in this trial and the study investigators and coordinators for their contributions to the study. Medical writing and editorial support were provided by Crystal Kellas, Ph.D., and graphical assistance was provided by Patrick Coughlin, under the guidance of the authors. We also thank John Pettersen and Jeffrey Wiley for their review of the manuscript. FVG, DA, PS, JK, LF, NA, WC are employees of Vertex Pharmaceuticals Incorporated and may own stock or stock options in the company.

References

1. Mall MA, Burgel PR, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL. Cystic fibrosis. *Nat Rev Dis Primers* 2024; 10: 53.

2. Pinquart M, Shen Y. Depressive symptoms in children and adolescents with chronic physical illness: an updated meta-analysis. *J Pediatr Psychol* 2011; 36: 375-384.

3. Quittner AL, Goldbeck L, Abbott J, Duff A, Lambrecht P, Sole A, Tibosch MM. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. *Thorax* 2014; 69: 1090-1097.

4. Graeber SY, Mall MA. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. *Lancet* 2023; 402: 1185-1198.

5. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. *Lancet* 2019; 394: 1940-1948.

6. Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, Tian S, Mall MA. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. *Am J Respir Crit Care Med* 2024; 209: 299-306.

7. Bathgate CJ, Fedele DA, Tillman EM, He J, Everhart RS, Reznikov LR, Liu FF, Kirby K, Raffensperger K, Traver K, Riekert KA, Powers SW, Georgiopoulos AM. Elexacaftor/tezacaftor/ivacaftor and mental health: A workshop report from the Cystic

Fibrosis Foundation's Prioritizing Research in Mental Health working group. *J Cyst Fibros* 2025; 24: 301-309.

8. Spoletini G, Gillgrass L, Pollard K, Shaw N, Williams E, Etherington C, Clifton IJ, Peckham DG. Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. *J Cyst Fibros* 2022; 21: 1061-1065.

9. Schneider EK, McQuade RM, Carbone VC, Reyes-Ortega F, Wilson JW, Button B, Saito A, Poole DP, Hoyer D, Li J, Velkov T. The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites. *ERJ Open Res* 2018; 4.

10. Kolski-Andreaco A, Taiclet S, Myerburg MM, Sembrat J, Bridges RJ, Straub AC, Wills ZP, Butterworth MB, Devor DC. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121. *J Clin Invest* 2024; 134.

11. VanElzakker MB, Tillman EM, Yonker LM, Ratai EM, Georgiopoulos AM. Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort. *Curr Opin Pulm Med* 2023; 29: 603-609.

12. Moser VC, McCormick JP, Creason JP, MacPhail RC. Comparison of chlordimeform and carbaryl using a functional observational battery. *Fundam Appl Toxicol* 1988; 11: 189-206.

13. Mathiasen JR, Moser VC. The Irwin Test and Functional Observational Battery (FOB) for Assessing the Effects of Compounds on Behavior, Physiology, and Safety Pharmacology in Rodents. *Curr Protoc Pharmacol* 2018; 83: e43.

14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic

reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009; 62: e1-34.

15. Tian R, Ge T, Kweon H, Rocha DB, Lam M, Liu JZ, Singh K, Biogen Biobank T, Levey DF, Gelernter J, Stein MB, Tsai EA, Huang H, Chabris CF, Lencz T, Runz H, Chen CY. Whole-exome sequencing in UK Biobank reveals rare genetic architecture for depression. *Nat Commun* 2024; 15: 1755.
16. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. *Nat Rev Drug Discov* 2010; 9: 929-939.
17. Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafo MR, Palmer T, Schooling CM, Wallace C, Zhao Q, Smith GD. Mendelian randomization. *Nat Rev Methods Primers* 2022; 2.
18. Kolli AR. Deriving protein binding-corrected chemical concentrations for in vitro testing. *Clin Transl Sci* 2023; 16: 2123-2129.
19. Miller AC, Comellas AP, Hornick DB, Stoltz DA, Cavanaugh JE, Gerke AK, Welsh MJ, Zabner J, Polgreen PM. Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. *Proc Natl Acad Sci U S A* 2020; 117: 1621-1627.
20. Rodriguez-Campos A, Ellison MJ, Perez-Grau L, Azorin F. DNA conformation and chromatin organization of a d(CA/GT)30 sequence cloned in SV40 minichromosomes. *EMBO J* 1986; 5: 1727-1734.
21. Catalan J, Ridge D, Hedge B, Cheshire A. Changing and unfinished narratives of the mental health impact of HIV in the UK. *SSM Qualitative Research in Health* 2024; 5.
22. Stein KSK, Andrykowski MA. Physical and psychological long-term and late effects of cancer. *Cancer* 2008; 112: 2577-2592.

23. Boas H, Van Citters AD, Yu EL, King JR, Zagnit EA, Dieni O, Ren CL. Impact of CFTR modulator therapy on basic life needs and financial concerns in people with cystic fibrosis: Data from the Well-ME survey. *J Cyst Fibros* 2025; 24: 660-666.

24. Tal-Alon N. When health changes everything: The disruptive side of identity shifts in people with CF. *Health (London)* 2025: 13634593251366025.

25. Handbook for Systematic Reviews of Interventions vesrion 6.4 (updated August 2023). In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor: Cochrane; 2024.

26. Allgood S, Levy R, Bubaris D, Riekert K, Psoter KJ, Lechtzin N. The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis. *Heliyon* 2023; 9: e20110.

27. DiMango E, Spielman DB, Overdevest J, Keating C, Francis SF, Dansky D, Gudis DA. Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis. Int Forum Allergy Rhinol, 2020/09/29 ed. Int Forum Allergy Rhinol; 2020. p. Online ahead of print.

28. Douglas JE, Civantos AM, Locke TB, Sweis AM, Hadjiliadis D, Hong G, Dorgan DJ, Kohanski MA, Palmer JN, Adappa ND. Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis. *Int Forum Allergy Rhinol* 2021; 11: 201-203.

29. Douglas T, Deery M, Kimball H, Cobham VE, Panochini S, Robinson PD, Wainwright CE, Sly PD, Blake T. Mental health, behaviour and sleep quality in children 6-11 years before and after elexacaftor/tezacaftor/ivacaftor initiation. *J Cyst Fibros* 2025; 24: 571-573.

30. Francesca B, Gloria T, Antonella S, Ilaria M, Emily P, Sandra P, Marco C. Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. *J Patient Rep Outcomes* 2025; 9: 48.

31. Garcia MS, Pelaez A, Punter RMG, Lopez MC, Carbajal CM, Ancochea J, Bachiller JME, Hernandez ASM, Rodrigo-Garcia M, Clemente MG, Moreno RMG. Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients. *BMC Pulm Med* 2025; 25: 81.

32. Graziano S, Boldrini F, Pellicano GR, Milo F, Majo F, Cristiani L, Montemitro E, Alghisi F, Bella S, Cutrera R, Fiocchi AG, Quittner A, Tabarini P. Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults. *Chest* 2024; 165: 800-809.

33. Gruber W, Welsner M, Blosch C, Dillenhoefer S, Olivier M, Brinkmann F, Koerner-Rettberg C, Sutharsan S, Mellies U, Taube C, Stehling F. Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy. *Healthcare (Basel)* 2023; 11.

34. Hevilla F, Porras N, Giron MV, Garcia-Olivares M, Padial M, Sanchez-Torralvo FJ, Olveira C, Olveira G. Impact of Elexacaftor-Tezacaftor-Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study. *Nutrients* 2024; 16.

35. Kos R, Neerincx AH, Fenn DW, Brinkman P, Lub R, Vonk SEM, Roukema J, Reijers MH, Terheggen-Lagro SWJ, Altenburg J, Majoor CJ, Bos LD, Haarman EG, Maitland-van der

Zee AH, Amsterdam Mucociliary Clearance Disease Research G. Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients. *Pharmacol Res Perspect* 2022; 10: e01015.

36. McCoy KS, Blind J, Johnson T, Olson P, Raterman L, Bai S, Eisner M, Sheikh SI, Druhan S, Young C, Pasley K. Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis. *Pediatr Pulmonol* 2023; 58: 1178-1184.
37. Nguyen M, MacDiarmid P, Tanzler A, Dagenais R, Bevanda C, Quon BS. Assessing the impact of elexacaftor/tezacaftor/ivacaftor on anxiety & depression symptom scores in adults with Cystic Fibrosis. *J Cyst Fibros* 2025; 24: 26-29.
38. Pasley K, Eisner M, Sliemers S, Young R, Dell ML, McCoy KS, May A. Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor-Tezacaftor-Ivacaftor Therapy. *Pediatr Pulmonol* 2025; 60: e27393.
39. Perez-Ruiz M, Te Bos M, Fernandez-Garcia P, Manuel C, Morales-Tirado A, Lopez-Neyra A, Valbuena MR, Rubio M, Sanz-Santiago V. Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6-11 Years: Actual Observations and Clinical Perspectives. *Arch Bronconeumol* 2025.
40. Pham H, Vandeleur M, Mainzer RM, Ranganathan S. Mental health, sleep, and respiratory health after initiating elexacaftor/tezacaftor/ivacaftor treatment in children with cystic fibrosis. *Pediatr Pulmonol* 2024; 59: 2606-2613.
41. Piehler L, Thalemann R, Lehmann C, Thee S, Rohmel J, Syunyaeva Z, Stahl M, Mall MA, Graeber SY. Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis. *Front Pharmacol* 2023; 14: 1179208.

42. Pudukodu H, Powell MZ, Ceppe A, Donaldson SH, Goralski JL, Sowa NA. Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis. *Clin Respir J* 2024; 18: e70007.

43. Sakon C, Vogt H, Brown CD, Tillman EM. A survey assessing the impact of COVID-19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis. *Pediatr Pulmonol* 2023; 58: 662-664.

44. Vincken S, Verbanck S, Braun S, Buyck N, Zienebergh C, Knoop C, Vanderhelst E. The Proof of the Pudding Is in the Eating: Real-Life Intra- and Extrapulmonary Impact of Elexacaftor/Tezacaftor/Ivacaftor. *Respiration* 2025; 104: 388-396.

45. Welsner M, Schulte T, Dietz-Terjung S, Weinreich G, Stehling F, Taube C, Strassburg S, Schoebel C, Sutharsan S. Effect of Triple Combination CFTR Modulator Therapy on Sleep in Adult Patients with Cystic Fibrosis. *Respiration* 2022; 101: 766-774.

46. Zhang L, Albon D, Jones M, Bruschwein H. Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis. *Ther Adv Respir Dis* 2022; 16: 17534666221144211.

Figure 1: Real World registry diagnoses of depression and anxiety pre and post ELX/TEZ/IVA initiation



Proportion of diagnosed depression (left panels) and anxiety (right panels) in people with cystic fibrosis (pwCF) before and after initiation of ELX/TEZ/IVA therapy. Data are shown for five years prior to and four years following treatment initiation, using US (top panel) and German (bottom) CF patient registries. Analyses included 8,967 patients in the US and 1,028 patients in Germany with non-missing data in all years; number of patients with non-missing data may vary across variables. Shaded area in Germany includes a mixture of pre-treatment and post-treatment data. The vertical dashed line indicates the time of ELX/TEZ/IVA initiation. Years in which these diagnoses were not collected in the registry are labelled N/A. Anxiety diagnoses were not captured by the German CF Registry in the pre-treatment period.

Figure 2 **Lack of human genetic association between *CFTR* variants and a broad spectrum of neuropsychiatric conditions in ~1 million individuals**



A. Results of gene burden test studies for class I CFTR protein-truncating variants across an unbiased set of 1,195 phenotypes from two biobanks comprising 644k samples in total. Each dot represents a phenotype and is placed on the x-axis and colored according to its category. The y-axis shows the p-value of the association, the grey and green dashed lines indicate the suggestive ($p < 1e-4$) and exome-wide ($p < 2.5e-6$) significance thresholds. Phenotypes that are associated with $p < 1e-4$ are labelled.

B. Results from class I CFTR protein-truncating variants burden tests in 16 neuropsychiatric disorders and mental health traits from 6 studies with up to 18,000 cases. The y-axis shows the p-value of the association, the grey and green dashed lines indicate the suggestive ($p < 1e-3$) and exome-wide ($p < 2.5e-6$) significance thresholds. The color indicates the number of cases included in the study.

C. GWAS association results between *F508del* and an unbiased set of 873 phenotypes in a biobank meta-analysis comprising over 1M individuals. Each dot represents a phenotype and is placed on the x-axis and colored according to its category. The y-axis shows the p-value of the association, the grey and green dashed lines indicate the suggestive ($p < 1e-5$) and genome-wide ($p < 5e-8$) significance thresholds. Phenotypes that are associated with $p < 1.1e-5$ are labelled.

D. GWAS association results between *F508del* and 23 neuropsychiatric disorders and mental traits from 21 studies with up to 192k cases. The y-axis shows the p-value of the association, the grey and green dashed lines indicate the suggestive ($p < 1e-3$) and exome-wide ($p < 5e-8$) significance thresholds. The color indicates the number of cases included in the study.

Table 1 Selectivity of ELX, TEZ, and IVA against major receptor and transporter families implicated in mental health disorders

Receptor Family	Sub-type	Reference compound	Reference compound IC_{50}	IVA		TEZ		ELX	
				IC_{50} (µM) binding Assay	Multiple vs. free [plasma] at C_{max} (0.0014µM)	IC_{50} (µM) binding Assay	Multiple vs. free [plasma] at C_{max} (0.133 µM)	IC_{50} (µM) binding Assay	Multiple vs. free [plasma] at C_{max} (0.108 µM)
Calcium Channels	L-type, Benzothiazepine[1]	Diltiazem	0.028 µM	>10	>7100	>10	>75	>10	>93
	L-type, Dihydropyridine[1]	Nitrendipine	0.27 nM	>10	>7100	>10	>75	>10	>93
	L-type, Phenylalkylamine[1]	Methoxyverapamil	15.4 nM	>10	>7100	>10	>75	>10	>93
	N-type[1]	w-conotoxin	0.050 nM	>10	>7100	>10	>75	>10	>93
Serotonin	$5\text{-}HT_{1A}$	Metergoline	1.88 nM	>10	>7100	>10	>75	>10	>93
	$5\text{-}HT_{1B}$[1]	Serotonin	11.8 nM	>10	>7100	>10	>75	>10	>93
	$5HT_{2B}$	Ketanserin	0.54 µM	4.81	3436	>10	>75	>10	>93
	$5\text{-}HT_{2C}$	SB242084	0.45 nM	0.876	626	>10	>75	>10	>93
	$5\text{-}HT_{3}$	MDL 72222	9.38 nM	>10	>7100	>10	>75	>10	>93
	$5\text{-}HT_{4}$[2]	RS-23597-190	0.083 µM	>10	>7100	>10	>75	>10	>93
	$5\text{-}HT_{5A}$	Methiothepin	1.6 nM	6.39	4564	>10	>75	9.1	84
	$5\text{-}HT_{6}$	Methiothepin	1.3 nM	>10	>7100	>10	>75	>10	>93
	$5\text{-}HT_{7}$	Methiothepin	0.57 nM	NT	NT	NT	NT	>10	>93

Receptor Family	Sub-type	Reference compound	Reference compound IC_{50}	IVA		TEZ		ELX	
				IC_{50} (µM) binding Assay	**Multiple vs. free [plasma] at C_{max} (0.0014µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.133 µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.108 µM)**
Dopamine	D_1	R(+)-SCH-23390	0.56 nM	>10	>7100	>10	>75	>10	>93
	D_{2S}	Spiperone	0.17 nM	>10	>7100	>10	>75	>10	>93
	D_3	Spiperone	0.36 nM	>10	>7100	>10	>75	>10	>93
	$D_{4.2}$	Spiperone	0.30 nM	>10	>7100	>10	>75	>10	>93
	D_5	R(+)-SCH-23390	1.13 nM	>10	>7100	>10	>75	>10	>93
Adrenergic	Adrenergic α_{1A} [1]	Prazosin	0.27 nM	>10	>7100	>10	>75	>10	>93
	Adrenergic α_{1B} [1] Adrenergic α_{1D}	Prazosin Prazosin	0.23 nM 0.40 nM	>10 >10	>7100 >7100	>10 >10	>75 >75	>10 >10	>93 >93
	Adrenergic α_{2A}	Yohimbine	2.25 nM	>10	>7100	>10	>75	>10	>93
	Adrenergic α_{2B}	Yohimbine	9.19 nM	NT	NT	NT	NT	>10	>93
	Adrenergic α_{2c}	Yohimbine	2.22 nM	8.73	6236	>10	>75	>10	>93
	Adrenergic β_1 Adrenergic β_2 Adrenergic β_3	S(-)-Propranolol S(-)-Propranolol Alprenolol	1.11 nM 0.38 nM 0.084 µM	>10 >10 5.2	>7100 >7100 3714	>10 >10 >10	>75 >75 >75	>10 >10 >10	>93 >93 >93
GABA	GABA A, Muscimol, Central [1]	GABA	0.039 µM	>10	>7100	>10	>75	>10	>93

Receptor Family	Sub-type	Reference compound	Reference compound IC_{50}	IVA		TEZ		ELX	
				IC_{50} (µM) binding Assay	**Multiple vs. free [plasma] at C_{max} (0.0014µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.133 µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.108 µM)**
	$GABA_A$, Flunitrazepam, Central[1]	Diazepam	15.5 nM	>10	>7100	>10	>75	>10	>93
	$GABA_{B1A}$	CGP-54626	3.35 nM	NT	NT	>10	>75	>10	>93
	$GABA_{B1B}$	CGP-54626	3.02 nM	NT	NT	>10	>75	>10	>93
	$GABA_B$, non-selective[1]	CGP-54626	1.24 nM	>10	>7100	NT	NT	NT	NT
	$GABA_A$, Cl^- Channel (TBOB)[1]	Picrotoxin	0.12 µM	>10	>7100	>10	>75	5.54	51
Glutamate	AMPA	L-Glutamic acid	0.15 µM	>10	>7100	>10	>75	>10	>93
	Kainate[1]	L-Glutamic acid	0.17 µM	>10	>7100	>10	>75	>10	>93
	NMDA, Agonism	L-Glutamic acid	0.15 µM	>10	>7100	>10	>75	>10	>93
	NMDA, Glycine	MDL 105,519	8.4 nM	>10	>7100	>10	>75	>10	>93
	NMDA Polyamine[1]	Ifenprodil	19.4 nM	>10	>7100	>10	>75	>10	>93
	NMDA, Phencyclidine[1]	Dizocilpine ((+)-MK-801)	2.21 nM	>10	>7100	>10	>75	>10	>93
Histamine	H_1	Pyrilamine	1.87 nM	>10	>7100	>10	>75	>10	>93
	H_2	Tiotidine	13.7 nM	1.37	979	>10	>75	>10	>93

Receptor Family	Sub-type	Reference compound	Reference compound IC_{50}	IVA		TEZ		ELX	
				IC_{50} (µM) binding Assay	**Multiple vs. free [plasma] at C_{max} (0.0014µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.133 µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.108 µM)**
	H_3	R(-)-α -Methylhistamine (RAMH)	1.97 nM	>10	>7100	>10	>75	>10	>93
	H_4	Histamine	12.4 nM	9.71	6936	>10	>75	>10	>93
Acetylcholine	Nicotinic	Epibatidine	0.10 nM	>10	>7100	>10	>75	>10	>93
	Muscarinic M_1	4-DAMP	6.43 nM	>10	>7100	>10	>75	>10	>93
	Muscarinic M_2	4-DAMP	0.029 µM	>10	>7100	>10	>75	>10	>93
	Muscarinic M_3	4-DAMP	3.86 nM	>10	>7100	>10	>75	>10	>93
	Muscarinic M_4	4-DAMP	11.6 nM	>10	>7100	>10	>75	>10	>93
	Muscarinic M_5	4-DAMP	1.93 nM	>10	>7100	>10	>75	>10	>93
Opioid	µ	DAMGO	10.8 nM	>10	>7100	>10	>75	>10	>93
	K	U-69593	0.021 µM	>10	>7100	>10	>75	>10	>93
	δ	Naltrindole	0.88 nM	>10	>7100	>10	>75	>10	>93
Cannabinoid	CB_1	R(+)-WIN-55,212-2	0.23 µM	>10	>7100	>10	>75	>10	>93
	CB_2	R(+)-WIN-55,212-2	8.61 nM	>10	>7100	>10	>75	>10	>93
Tachykinin	NK_1	L-703,606	4.97 nM	>10	>7100	>10	>75	>10	>93
	NK_2	MEN-10,376	0.04 µM	3.54	2529	>10	>75	>10	>93

Receptor Family	Sub-type	Reference compound	Reference compound IC_{50}	IVA		TEZ		ELX	
				IC_{50} (µM) binding Assay	**Multiple vs. free [plasma] at C_{max} (0.0014µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.133 µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.108 µM)**
	NK_3	Senktide	0.036 µM	>10	>7100	>10	>75	>10	>93
Somatostatin	sst1	Somatostatin-14	0.36 nM20	9.5	6786	>10	>75	>10	>93
	sst2	Somatostatin-14	9.64 pM	>10	>7100	>10	>75	>10	>93
	sst3	Somatostatin-14	0.13 nM	>10	>7100	>10	>75	>10	>93
	sst4	Somatostatin-14	0.34 nM	5.25	3750	>10	>75	>10	>93
	sst5	Somatostatin-14	0.56 nM	>10	>7100	>10	>75	>10	>93
Adenosine	A_1	R(-)-PIA	0.31 µM	>10	>7100	>10	>75	>10	>93
	A_{2A}	CGS-21680	0.091 µM	>10	>7100	>10	>75	>10	>93
	A_{2B}	DPCPX	0.18 µM	NT	NT	NT	NT	>10	>93
	A_3	IB-MECA	1.27 nM	6.96	4971	>10	>75	>10	>93
Melatonin	MT (non-selective)	6-Chloromelatonin	0.937 nM	>10	>7100	NT	TN	NT	NT
	MT_1	Melatonin	0.27 nM	NT	NT	>10	>75	>10	>93
	MT_2	4-P-PDOT	0.34 nM	NT	NT	>10	>75	>10	>93
Orexin	OX_1	Orexin A	0.35 nM	NT	NT	NT	NT	>10	>93
	OX_2	Orexin B	0.11 nM	NT	NT	NT	NT	>10	>93
Transporters	Adenosine [2]	Nitrobenzylthioinosine	0.45 nM	>10	>7100	>10	>75	>10	>93

Receptor Family	Sub-type	Reference compound	Reference compound IC_{50}	IVA		TEZ		ELX	
				IC_{50} (µM) binding Assay	**Multiple vs. free [plasma] at C_{max} (0.0014µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.133 µM)**	**IC_{50} (µM) binding Assay**	**Multiple vs. free [plasma] at C_{max} (0.108 µM)**
	Choline [1]	Hemicholinium-3	2.71 nM	>10	>7100	>10	>75	>10	>93
	Dopamine (DAT)	GBR-12909	2.14 nM	1.61	1150	>10	>75	>10	>93
	GABA	NO-711	0.12 µM	>10	>7100	>10	>75	>10	>93
	Glycine	Sarcosine	82.1 µM	NT	NT	NT	NT	>10	>93
	Serotonin (SERT)	Fluoxetine	14.1 nM	>10	>7100	>10	>75	>10	>93
	Monoamine [3]	Ketanserin	7.43 nM	0.846	604	>10	>75	NT	NT
	Monoamine, vesicular (hum)	Tetrabenazine	2.45 nM	NT	NT	NT	NT	>10	>93
	Norepinephrine	Desipramine	0.49 nM	1.46	1043	>10	>75	>10	>93

NT: not tested

All receptors human except for those marked as rat [1], guinea pig [2], or rabbit [3.]

Table 2 Tissue distribution of ^{14}C-ELX, ^{14}C-TEZ and ^{14}C-IVA at the C_{max} following oral administration to Male Sprague Dawley Rats

	^{14}C-ELX (10 mg/kg)	^{14}C-TEZ (30 mg/kg)	^{14}C-IVA (10 mg/kg)
C_{max} in Brain (µg eq/g*)	2.12	1.99	0.0879
C_{max} in Plasma (µg eq/g*)	9.29	5.16	3.16
C_{max} Ratio (Brain/Plasma)	0.228	0.39	0.03

* µg eq/g is µg equivalents ^{14}C material per gram of brain or plasma

Table 3 Clinical and FOB observations following oral gavage administration of Chlorpromazine, IVA, TEZ, or ELX in female or male rats

Test Article	Test [1]	Dose mg/kg [2]	Mortality [3]	Test-article related neurobehavioral observations
Chlorpromazine (reference)	Irwin	20	None	Abnormal gait, decreased touch response, catalepsy, decreased body tone, decreased touch response, ptosis, increased vocalization, increased urination, and decreased grooming.
Ivacaftor (IVA)	Irwin	0, 250, 500, 1000	None	None
Tezacaftor (TEZ)	FOB	0, 20, 60, 200	None	None
Elexacaftor (ELX)	FOB	0, 5, 15, 30	None	None

[1] Neurobehavioral effects were evaluated using established protocols in three separate studies: Irwin Test (IVA and chlorpromazine): Comprehensive assessment of autonomic, neuromuscular, sensorimotor, and behavioral domains at 2, 4, 8, and 24 hours post-dose; Functional Observational Battery (FOB) (ELX, TEZ): Assessment of activity/arousal, autonomic, neuromuscular, sensorimotor, and physiological parameters at baseline and at 4 or 6 and 24 hours post-dose (see **Table E1** for list of individual endpoints). [2] Single oral administration of IVA or chlorpromazine to male rats (6 animals per dose group), TEZ to male rats (10 animals per dose group), or ELX to female rats (10 animals per dose group). [3] No mortalities during test period.

Table 4 Exposure-Adjusted Summary of Relevant Psychiatric AEs Among CFTR Modulator Regimens: Pivotal Placebo-Controlled Phase 3 and Open-Label Extension Studies in CF Subjects

	ELX/TEZ/IVA			TEZ/IVA			LUM/IVA			IVA		
	24w, PBO-controlled		4y, OLE	Pooled 24w, PBO-controlled		2y, OLE	Pooled 24w, PBO-controlled		2y, OLE	Pooled 48-wk, PBO-controlled		2y, OLE
Events/ 100PY	**PBO N=201**	**ETI N=202**	**ETI N=506**	**PBO N = 505**	**T/I N=496**	**T/I N=1042**	**PBO N=370**	**L/I N=738**	**L/I N=1029**	**PBO N=104**	**IVA N=109**	**IVA N=192**
Relevant Psychiatric Events	8.01	8.98	8.27	10.94	6.48	7.51	16.47	8.74	6.32	4.13	5.57	7.17
Relevant Psychiatric Serious Events [a]	2.00	0	0.38	0	0	0.72	1.10	0	0.41	1.03	0	0.80
Relevant Psychiatric Events leading to Discontinuation	0	0	0.05	0	0	0.13	0	0	0	1.03	0	0.27

AE: adverse event; CF: cystic fibrosis; CFTR: CF transmembrane conductance regulator protein; ETI: triple combination therapy with elexacaftor, tezacaftor, and IVA; IVA: ivacaftor; L/I: lumacaftor in combination with IVA; N: total sample size; OLE: open-label extension study; PBO: placebo; PY: person-year; SAE: serious AE; T/I: tezacaftor in combination with IVA. Events/100PY: number of events per 100 PY = number of events/total duration of safety analysis period in 100PY.
Notes: When summarizing number of events, a subject with multiple events within a category is counted multiple times in that category.

[a] Relevant psychiatric preferred terms comprise abnormal behavior, anxiety, completed suicide, depression, depressed mood, depression suicidal, emotional disorder, insomnia, mental disorder, mood altered, sleep disorder, suicide attempt, suicidal behavior, suicidal ideation, and suicide threat. Note that there were no reported events of abnormal behavior, completed suicide, mood altered, suicidal behavior and suicide threat in patients treated with CFTR modulators or placebo.

Supplemental Appendix

Supplemental Methods

Rat neurobehavioral studies

Animal studies and dosing

Sprague Dawley rats (male or female, depending on compound) at least 6 weeks of age at study start were acclimated and randomly assigned to treatment groups. Each CFTR modulator—elexacaftor (ELX), tezacaftor (TEZ), or ivacaftor (IVA)—was administered as a single oral gavage at three dose levels, with vehicle controls included in all studies. For the IVA study, a positive control group received chlorpromazine (20 mg/kg) to confirm assay sensitivity. Animal behavioral studies were conducted by Aptuit, Inc. Kansas City Missouri (Irwin test: IVA) or MPI Research, Inc. Mattawan, Michigan (FOB: TEZ and ELX) in accordance with the United States Food and Drug Administration Good Laboratory Practice Standards.

Behavioral assessments

Neurobehavioral effects were evaluated using established protocols: 1) Irwin Test (IVA): Comprehensive assessment of autonomic, neuromuscular, sensorimotor, and behavioral domains at 2, 4, 8, and 24 hours post-dose; Functional Observational Battery (FOB) (ELX, TEZ): Assessment of activity/arousal, autonomic, neuromuscular, sensorimotor, and physiological parameters at baseline and at 4 or 6 and 24 hours post-dose (**Table E1**). Body weight and temperature were monitored throughout. All animals were observed for morbidity, mortality, and general health at least twice daily.

Formulation and Data Analysis

Test articles were suspended in methylcellulose-based vehicle and administered within hours of preparation. Dosing formulations were analyzed for concentration and homogeneity using validated HPLC-UV methods; all met acceptance criteria.

Data were compared between treated and control groups to identify neurobehavioral changes. For FOB endpoints (TEZ, ELX), statistical comparisons between treatment and vehicle treated groups included Group Pair-wise Comparisons (continuous endpoints) or Cochran Mantel Haenszel Test (Categorical Endpoints). For the Irwin test (IVA, Chlorpromazine), only deviations from normal were recorded.

Study Termination

At study completion, animals were euthanized by carbon dioxide inhalation followed by a secondary method to confirm death. No postmortem evaluations were scheduled unless required for unexpected deaths.

Determination of the free concentration at the C_{max} for ELX, TEZ, and IVA

The free fractions of ELX, TEZ, and IVA in human plasma were determined using equilibrium dialysis method. The 3 mM stock solutions of ELX, TEZ, and IVA were prepared from compound powder using DMSO. Diluted plasma was prepared by adding an appropriate amount of blank plasma to the dialysis phosphate buffer. Into separate vials for each compound were spiked into diluted plasma at a final concentration of 5 µM (1% organic). The control compound, warfarin, was spiked into the undiluted plasma at 5 µM. The spiked diluted or undiluted plasma was loaded into the plasma compartment (red side) of the Rapid Equilibrium Dialysis (RED) device (200 µL; n = 4 per condition). Phosphate buffer was loaded into the buffer compartment (white side) of the RED device (350 µL; n = 4 per condition). The RED device was sealed with

breathable sealing tape and then an adhesive sealing tape from ThermoFisher Scientific (Waltham, MA). The device was agitated gently on a shaking platform at 150 rpm in a CO_2 incubator (5% CO_2) for 18 hours at 37°C with saturating humidity. After 18-hour incubation, 20 µL from the plasma side and 20 µL from the buffer side of each RED well were added into an equal amount of the opposite blank matrix. Samples were mixed with 480 µL of Internal Standard solution in acetonitrile to precipitate proteins (i.e., 20 µL of sample plasma + 20 µL of blank sodium phosphate buffer; 20 µL of sample buffer + 20 µL of blank diluted plasma). Samples were vortexed and centrifuged at 12000 rpm for 11 minutes. The supernatants were injected for LC-MS/MS analysis. Compounds bound to plasma proteins do not cross the dialysis membrane. The fraction bound can thus be calculated from the difference between the compound concentrations in the plasma (donor) and buffer (receiver) samples.

Rat brain distribution studies

The tissue distribution of ^{14}C-IVA was studied in male Sprague-Dawley rats following oral administration at 10 mg/kg with the dose formulated polyethylene glycol (PEG) 400 with a dose volume of 5 mL/kg. The targeted radioactive dose of ^{14}C-IVA was 100 µCi/kg. Tissue concentrations were determined at 1, 4, 24, 48,72, and 168 hours post dosing.

The tissue distribution of ^{14}C-TEZ was studied in male Sprague-Dawley rats following oral administration at 30 mg/kg with the dose formulated in 37.5% PEG 400/12.5% Vitamin E-TPGS in water with a dose volume of 5 mL/kg. The targeted radioactive dose of 14C-TEZ was 100 µCi/kg. Tissue concentrations were determined at 1, 4, 24, 48, 72, and 168 hours post dosing.

The tissue distribution of ^{14}C-ELX was studied in male Sprague Dawley rats following oral administration at 10 mg/kg with the dose formulated in 5% NMP/30% PEG 400/10% TPGS/5%

PVP VA in water with a dose volume of 10 mL/kg. The targeted radioactive dose of 14C-VX-445 was 100 µCi/kg. Tissue concentrations were determined at 1, 4, 24 and 168 hours post dosing.

Systematic Review of Published Literature

The SLR search included peer-reviewed publications published from 2019 (first ELX/TEZ/IVA approval in the US) through May 7, 2025 (date of search) with the following key criteria: includes people with a diagnosis of CF treated with ELX/TEZ/IVA, reports on mental health outcomes measured using validated instruments or objective pre-defined patient- or caregiver-reported measures, and has data available prior to and after ELX/TEZ/IVA initiation (to assess post-treatment changes).

Searches for this SLR were conducted across multiple databases with the Ovid® search interface (Embase, Ovid MEDLINE®, and the Cochrane Central Register of Controlled Trials) using a combination of controlled vocabulary and keywords by a medical information specialist and peer reviewed by another senior medical information specialist before execution (**Figure E1**). The initial search was not restricted by language. Study eligibility was assessed according to pre-specified Population, Intervention, Comparator, Outcome, and Study Design (PICOS) criteria (25) and was performed in duplicate by two independent reviewers. Data from included records were extracted using a standardized approach by a single reviewer. Data were then independently assessed for accuracy and completeness by a second reviewer. All conflicts were resolved through consensus or by a third independent reviewer.

Figure E1. PRISMA flow diagram



Table E1. Functional neurobehavioral domains assessed for IVA (Irwin test) or TEZ and ELX (FOB tests)

Domain	Irwin Test Items	FOB Items
Mortality & General Health	Lethality, Cyanosis, Hypothermia	Body weight, Body temperature
Locomotor & Activity	Locomotor activity, Restlessness, Lethargy, Grooming, Dispersion in cage	Rearing, Posture, Arousal
Neuromuscular Function	Tremor, Twitches, Convulsions, Abnormal carriage/gait, Paralysis, Grip strength, Body tone, Catalepsy/passivity, Straub tail	Tremor, Convulsions, Forelimb/hindlimb grip strength, Hindlimb splay, Clonic/tonic movements, Gait, Stereotypy
Behavioral & Psychiatric-like Signs	Stereotypic behavior, Fighting, Aggressiveness, Fearfulness, Vocalization	Handling reactivity, Ease of removal, Vocalization, Bizarre behavior
Reflexes & Sensorimotor	Startle response/loss of righting reflex, Pinna reflex, Corneal reflex, Pain response	Thermal response, Approach/touch/click/tail pinch response, Pupil response, Righting reflex
Autonomic	Salivation, Lacrimation, Ptosis, Pupil diameter, Diarrhea, Increased urination, Cutaneous blood flow, Piloerection, Exophthalmia	Defecation, Urination, Lacrimation, Palpebral closure, Piloerection, Exophthalmos, Salivation, Pupil response
Physiological	Respiration, Cyanosis, Hypothermia, Body tone	Respiration, Body weight, Body temperature
Other	Writhing, Catalepsy/passivity, Cutaneous blood flow	

Table E3 Exposure-Adjusted Summary of Relevant Psychiatric AEs by Preferred Term Among CFTR Modulator Regimens: Pivotal Placebo-Controlled Phase 3 and Open-Label Extension Studies in CF Subjects

Events/ 100PY PT	ELX/TEZ/IVA			TEZ/IVA			LUM/IVA			IVA		
	24w, PBO-controlled		4y, OLE	Pooled 24w, PBO-controlled		2y, OLE	Pooled 24w, PBO-controlled		2y, OLE	Pooled 48-wk, PBO-controlled		2y, OLE
	PBO N=201	ETI N=202	ETI N=506	PBO N = 505	T/I N=496	T/I N=1042	PBO N=370	L/I N=738	L/I N=1029	PBO N=104	IVA N=109	IVA N=192
Relevant Psychiatric Events[a]	8.01	8.98	8.27	10.94	6.48	7.51	16.47	8.74	6.32	4.13	5.57	7.17
Anxiety	1.00	2.99	2.79	3.45	0.59	2.17	2.20	2.26	2.09	1.03	1.86	3.19
Depression	2.00	1.00	2.57	2.30	1.18	2.11	3.84	1.13	1.85	1.03	0	1.06
Depressed mood	0	1.00	0.11	0	0	0.20	0	0.85	0.35	0	0	0
Depression suicidal	0	0	0	0	0	0	0	0	0	0	0	0.27
Emotional disorder	0	0	0	0	0	0	0.55	0	0	0	0	0
Insomnia	1.00	2.99	2.14	4.03	3.54	2.70	8.23	3.38	1.80	1.03	2.78	1.59
Mental disorder	0	0	0.05	0	0	0	0	0.28	0	0	0	0
Mood altered	0	0	0	0	0	0	0	0.28	0	0	0	0
Sleep disorder	3.00	1.00	0.27	1.15	1.18	0.07	0.55	0.28	0.06	1.03	0.93	0.80
Suicidal ideation	1.00	0	0.16	0	0	0.07	0.55	0.28	0.12	0	0	0.27
Suicide attempt	0	0	0.16	0	0	0.20	0.55	0	0.06	0	0	0
Relevant Psychiatric Serious Events	2.00	0	0.38	0	0	0.72	1.10	0	0.41	1.03	0	0.80
Anxiety	0	0	0.16	0	0	0.33	0	0	0.12	1.03	0	0
Depression	1.00	0	0.05	0	0	0.13	0	0	0.17	0	0	0.27
Depression suicidal	0	0	0	0	0	0	0	0	0	0	0	0.27
Mental disorder	0	0	0.05	0	0	0	0	0	0	0	0	0

Events/ 100PY PT	ELX/TEZ/IVA			TEZ/IVA			LUM/IVA			IVA		
	24w, PBO-controlled		4y, OLE	Pooled 24w, PBO-controlled		2y, OLE	Pooled 24w, PBO-controlled		2y, OLE	Pooled 48-wk, PBO-controlled		2y, OLE
	PBO N=201	ETI N=202	ETI N=506	PBO N = 505	T/I N=496	T/I N=1042	PBO N=370	L/I N=738	L/I N=1029	PBO N=104	IVA N=109	IVA N=192
Suicidal ideation	1.00	0	0	0	0	0.07	0.55	0	0.06	0	0	0.27
Suicide attempt	0	0	0.11	0	0	0.20	0.55	0	0.06	0	0	0
Relevant Psychiatric Events leading to Discontinuation	0	0	0.05	0	0	0.13	0	0	0	1.03	0	0.27
Anxiety	0	0	0	0	0	0.07	0	0	0	1.03	0	0
Depression	0	0	0.05	0	0	0.07	0	0	0	0	0	0
Depression suicidal	0	0	0	0	0	0	0	0	0	0	0	0.27

AE: adverse event; CF: cystic fibrosis; CFTR: CF transmembrane conductance regulator protein; ETI: elexcaftor/tezacaftor/ivacaftor, and IVA; IVA: ivacaftor; L/I: lumacaftor in combination with IVA; N: total sample size; OLE: open-label extension study; PBO: placebo; PY: person-year; SAE: serious AE; T/I: tezacaftor in combination with IVA; y: year(s). Events/100PY: number of events per 100 PY = number of events/total duration of safety analysis period in 100PY.
Notes: When summarizing number of events, a subject with multiple events within a category is counted multiple times in that category.

[a] Relevant psychiatric preferred terms comprise abnormal behavior, anxiety, completed suicide, depression, depressed mood, depression suicidal, emotional disorder, insomnia, mental disorder, mood altered, sleep disorder, suicide attempt, suicidal behavior, suicidal ideation, and suicide threat. Note that there were no reported events of abnormal behavior, completed suicide, mood altered, suicidal behavior and suicide threat in patients treated with CFTR modulators or placebo.

Table E4 Characteristics and Demographics of Relevant Psychiatric Preferred Terms for IVA, LUM/IVA, TEZ/IVA, and ELX/TEZ/IVA from Ph2 and Ph3 Clinical Trial Experience in pwCF

Parameter		Placebo (Pooled - all CFTRm) N= 1,887 n (%)	ELX/TEZ/IVA N= 2,032[c] n (%)	TEZ/IVA N= 1,849[c] n (%)	LUM/IVA N= 1,770[c] n (%)	IVA N= 1,101[c] n (%)
	Relevant psychiatric AEs/100PY[b]	9.6	All 4 CFTR modulators: 6.9			
			9.4	5.7	5.3	5.8
	Subjects with relevant psychiatric AE [a]	64 (3.4)	263 (12.9)	144 (7.8)	149 (8.4)	57 (5.2)
Number of subjects with psychiatric events, N1		**N1=64 n/N1, %**	**N1=263 n/N1, %**	**N1=144 n/N1, %**	**N1=149 n/N1, %**	**N1=57 n/N1, %**
Seriousness	Serious	4 (6.3)	14 (5.3)	14 (9.7)	7 (4.7)	6 (10.5)
	Non-serious	60 (93.8)	249 (94.7)	130 (90.3)	142 (95.3)	51 (89.5)
	Fatal	0	0	0	0	0
Age	Aged <18 years	13 (20.3)	64 (24.3)	27 (18.8)	35 (23.5)	15 (26.3)
	Aged ≥18 years	51 (79.7)	199 (75.7)	117 (81.3)	114 (76.5)	42 (73.7)
Sex	Male	24 (37.5)	113 (43.0)	49 (34.0)	54 (36.2)	25 (43.9)
	Female	40 (62.5)	150 (57.0)	95 (66.0)	95 (63.8)	32 (56.1)
Past medical history of psychiatric condition	Yes	25 (39.1)	125 (47.5)	66 (45.8)	56 (37.6)	22 (38.6)
	No	39 (60.9)	138 (52.5)	78 (54.2)	93 (62.4)	35 (61.4)

AE: adverse event; CFTRm: cystic fibrosis transmembrane conductance regulator modulators; ELX: elexacaftor; IVA: ivacaftor; LUM: lumacaftor; n is the number of subjects reported per category; N is number of subjects treated per product; PT: preferred term; TE: treatment emergent; TEZ: tezacaftor

[a] Relevant Psychiatric PTs: Abnormal behaviour, Anxiety, Completed Suicide, Depression, Depressed mood, Depression suicidal, Emotional disorder, Insomnia, Mental disorder, Mood altered, Sleep disorder, Suicide attempt, Suicidal behaviour, Suicidal ideation, and Suicide threat.

[b] Events/100PY: number of events per 100 patient years (336 days = 48 weeks per year) = number of events / (total duration of cumulative treatment-emergent period / (336*100)).

[c] Subjects exposed to multiple treatments are included in the safety sets for each treatment. Subjects treated with multiple modulator treatments in multiple treatment arms or open-label extension studies are counted once under each modulator.

- Included all subjects with CF aged 1 month and older who received at least 1 dose of study drug (either placebo or in approved dose) from Phase 2 and 3 controlled and uncontrolled studies in IVA, LUM/IVA, TEZ/IVA, and ELX/TEZ/IVA programs. For 809-102/103/104/105 studies, subjects on the 2 doses evaluated in the pivotal Phase 3 studies or placebo in the study safety sets are included.
- A subject is considered in the serious category if there is at least 1 serious event.
- Age and sex are based on the initial exposure of the corresponding treatment.

Table E4 Characteristics and Demographics of Relevant Psychiatric Preferred Terms for IVA, LUM/IVA, TEZ/IVA, and ELX/TEZ/IVA from Ph2 and Ph3 Clinical Trial Experience in pwCF

- Past medical history of psychiatric condition is identified as having any event in the System Organ Class (SOC) of Psychiatric disorders, in the medical history of the earliest study associated with the treatment of the subjects.
- AEs are all treatment emergent, defined as AEs started during a cumulative treatment emergent (TE) period, which is defined as the time frame that the subject did not switch to a different treatment and did not have a gap of study participation (e.g., gaps between Phase 2 and Phase 3 studies, or protocol defined wash-out period). The beginning of a cumulative TE period is the date of initial dose of the treatment, and the end of a cumulative TE period is the end of the last TE period (as defined in individual study) within this cumulative TE period.

Table E5. Summary of results from 21 studies identified via systematic literature review

Study (author, year)	Patients[a]	Follow-up post-treatment initiation	Score Change Post-treatment			
			Depression	Anxiety	Sleep	Other
Allgood, 2023 (26)	22 adults, US	14, 28, 42, 56, 70, 84, 98 days	No change in PHQ-8 BL mean: 4.9 FU mean: 2.9 to 4.3 P-value: not significant (value not reported)	No change in GAD-7 BL mean: 4.1 FU mean: 2.5 to 3.3 P-value: not significant (value not reported)	Improvement in PSQI sleep quality BL mean: 7.1, FU mean: 4.6 to 6.2 P-value: significant (value not reported)	
DiMango, 2021 (27)	43 adults, US	3 months			Improvement in SNOT-22 sleep domain BL mean: 6.8 FU mean: 5.1 P-value: <0.05	Improvement in SNOT-22 psychologic domain BL mean: 11.8 FU mean: 9.3 P-value: <0.05 No change in CFQ-R emotion domain BL mean: 73.3 FU mean: 76.0 P-value: ≥0.05
Douglas, 2021 (28)	25 adults, US	5 months			No change in SNOT-22 sleep domain BL mean: 8.6 FU mean: 8.1 P-value: 0.58	No change in SNOT-22 psychologic domain BL mean: 8.1 FU mean: 6 P-value: 0.06
Douglas, 2025 (29)	108 children (age 6-11 years), Australia	1 month			No change in total SDSC Median change from BL: +1 P-value: 0.97	No change in PSC-17 Median change from BL: 0 P-value: 0.61
Francesca 2025 (30)	181 adults and children, Italy	12, 24, 36 months				Improvement in CFQ-R emotion domain BL mean: 73.3 FU mean: 80.0 to 86.7 P-value: <0.05
Garcia, 2025 (31)	108 adults, Spain	3, 6, 12 months	No change in PHQ-9 Median change from	No change in GAD-7 Median change from BL:		Improvement in CFQ-R emotion domain

Study (author, year)	Patients[a]	Follow-up post-treatment initiation	Score Change Post-treatment			
			Depression	Anxiety	Sleep	Other
			BL: -0.5 to -1.5 P-value: 0.14 to 0.19	-1 to -2 P-value: 0.09 to 0.43		Median change from BL: 0 to 13.33 P-value: <0.001 to 0.02
Graziano, 2024 (32)	92 adults and children, Italy	1, 3, 6 months	Improvement in PHQ-9 BL mean: 3.7 FU mean: 2.7 to 2.9 P-value: 0.001	No change in GAD-7 BL mean: 3.7, FU mean: 3.1 to 3.6 P-value: 0.37		No change in CFQ-R emotion domain BL mean: 80.1 FU mean: 83.6 to 84.4 P-value: 0.15
Gruber, 2023 (33)	21 adults, Germany	Mean 5.6 ± 0.8 years				Improvement in CFQ-R emotion domain BL mean: 75.9 FU mean: 87.1 P-value: 0.046
Hevilla, 2024 (34)	31 adults, Spain	12 months	No change in HADS-D BL mean: 2.9 FU mean: 2.5 P-value: 0.52	No change in HADS-A BL mean: 4.9 FU mean: 4.6 P-value: 0.64		No change in CFQ-R emotion domain BL mean: 84.5 FU mean: 84.3 P-value: 0.94
Kos, 2022 (35)	20 adults and children, Netherlands	12 months				No change in CFQ-R emotion domain BL mean: 67.9 FU mean: 76.1 P-value: 0.16
McCoy, 2023 (36)	18 adults and children, US	1, 3, 6, 12, 24 months				No change in CFQ-R emotion domain BL median: 73.3 FU median: 80.0 to 86.7 P-value: 0.17
Nguyen, 2025 (37)	100 adults, Canada	6, 12 months	Improvement in PHQ-9 Mean change from BL: -1 P-value: <0.001	Improvement in GAD-7 Mean change from BL: -1 P-value: 0.03		
Pasley, 2025 (38)	81 children, US	1, 3, 6, 9, 12, 18 months	No change in PHQ-8 Mean change from BL: -1.3 P-value: 0.13	Improvement in GAD-7 Mean change from BL: -1.2 to -1.4 P-value: 0.01 to 0.04		

Study (author, year)	Patients[a]	Follow-up post-treatment initiation	Score Change Post-treatment			
			Depression	Anxiety	Sleep	Other
			Improvement in PROMIS-D Mean change from BL : -2.3 to -3.4 P-value: <0.01 to 0.04	Improvement in PROMIS-A Median BL: 41 Median FU: decreased, value not reported P-value: significant, value not reported		
Perez-Ruiz, 2025 (39)	28 children, Spain	6 to 8 months				Improvement in CFQ-R emotion domain Mean BL: 78.0 Mean FU: 84.0 P-value: 0.005
Pham, 2024 (40)	31 children, Australia	18 months	No change in PHQ-9 BL mean: 6.4 FU mean: 6.6 Change from BL: 0.24 P-value: 0.83	No change in GAD-7 BL mean: 5.3 FU mean: 5.9 Change from BL: 0.52 P-value: 0.66	No change in SDSC, sleep disturbance BL mean: 43 FU mean: 42.9 Change from BL: -0.1 P-value: 0.96 No change in PDSS, sleep disturbance BL mean: 11.5 FU mean: 11.7 Change from BL: 0.2 P-value: 0.85	
Piehler, 2023 (41)	70 adults, Germany	8 to 16 weeks	Improvement in PHQ-9 Median change from BL: -1 P-value: 0.05 Improvement in BDI-FS BL median: 1 FU median: 0 P-value: <0.05	No change in GAD-7 Median BL: 2.0 Median FU: 2.0 P-value: 0.11		No change in CFQ-R emotion domain BL median: 80 FU median: 80 P-value: 0.37
Pudukodu, 2024 (42)	86 adults, US	6 months	No change in PHQ-9 BL mean: 5 FU mean: 4.8 P-value 0.97	No change in GAD-7 BL mean: 4.9 FU mean: 5.3 P-value: 0.41		

Study (author, year)	Patients[a]	Follow-up post-treatment initiation	Score Change Post-treatment			
			Depression	Anxiety	Sleep	Other
Sakon, 2023 (43)	56 adults, US	3 to 6 months	No change in PHQ-9 Median change from BL: -1.11 P-value: not reported			
Vincken, 2025 (44)	79 adults, Belgium	3, 6 months	No change in PHQ-9 BL median: 4 FU median: 3 P-value: >0.05	No change in GAD-7 BL median: 3 FU median: 2-3 P-value: >0.05		
Welsner, 2022 (45)	29 adults, Germany	Mean 194 ± 21 days			No change or improvement across PSG indices Change from BL: varied P-value: <0.001 to 0.76	
Zhang, 2022 (46)	100 adults, US	Not reported	No change in PHQ-9 BL mean: 5, FU mean: 5.1 P-value: 0.9	No change in GAD-7 BL mean: 4.3, FU mean: 4.5 P-value: 0.8		

Note: Studies organized alphabetically by last name of first author.

[a] The total number of patients in the study was provided where available; sample size for each outcome based on the number of patients with non-missing data. Information about inclusion of adults, pediatrics, or both are specified where provided in the publication.

BL: baseline; FU: follow-up; BDI-FS: Beck Depression Inventory-Fast Screen; CFQ-R: Cystic Fibrosis Questionnaire-Revised; GAD-7: Generalized Anxiety Disorder 7-item scale; HADS-A: The Hospital Anxiety and Anxiety Scale ; HADS-D: The Hospital Anxiety and Depression Scale ; PDSS: The Pediatric Daytime Sleepiness Scale; PHQ-8: The Patient Health Questionnaire-8; PHQ-9: The Patient Health Questionnaire-9; PROMIS-A: PROMIS Anxiety; PROMIS-D: PROMIS Depression; PSC-17: Pediatric Symptom Checklist-17; PSG: polysonography; PSQI: Pittsburgh Sleep Quality Index; SDSC: The Sleep Disorder Scale for Children; SNOT-22: The Sino-Nasal Outcome Test.

Table E6a. Results of phenome-wide human genetics association tests in biobanks

Study	Variant used	Phenotype	Reference[1-3]	Cases	Controls	beta	P-Value
PTV burden	PTV burden	Glycated haemoglobin (HbA1c)	Genebass	376931		-4.41e-03	2.38e-07
	PTV burden	Staphylococcus infections	All by all	1668	167839	4.83e+00	1.35e-06
	PTV burden	Staphylococcus aureus	All by all	1215	169867	4.58e+00	4.68e-06
	PTV burden	Staphylococcus	All by all	1480	169273	4.45e+00	8.59e-06
	PTV burden	Mucolytics	All by all	2252	167711	4.32e+00	1.55e-05
	PTV burden	Methicillin resistant Staphylococcus aureus	All by all	1504	169800	4.27e+00	1.96e-05
	PTV burden	Drug resistant microorganisms	All by all	1918	168804	4.17e+00	3.04e-05
	PTV burden	Vitamin K	All by all	2489	167474	4.10e+00	4.14e-05
	PTV burden	Pneumonia	All by all	6683	155193	4.09e+00	4.33e-05
	PTV burden	Bronchiectasis	All by all	736	98332	3.90e+00	9.64e-05
F508del GWAS	F508del	Aspergillosis	FinnGen/UKB	643	869345	1.05e+00	7.41e-08
	F508del	Chronic pancreatitis	FinnGen/UKB	5717	824949	5.88e-01	3.43e-07

PTV burden tests reported in this table are limited to associations with at least suggestive PTV burden p-value (1e-4). F508del and rs10255092 GWAS results are limited to results associated with at least GWAS suggestive p-value (1e-5).

Table E6b. Results of human genetics association tests with 23 neuropsychiatric traits

Study	Variant used	Phenotype	Reference[1, 2, 4-29]	Cases	Controls	beta	P-Value
PTV burden	PTV burden	Neuroticism	Genebass	320534		1.98e-04	8.43e-01
	PTV burden	Schizophrenia	SCHEMA	24248	97322	-1.59e-01	6.01e-01
	PTV burden	Anxiety	Genebass	18338	376503	2.43e-03	5.83e-01
	PTV burden	Bipolar	BipEx	13933	14422	-1.06e+00	1.47e-01
	PTV burden	Substance addiction and disorders	All by all	10827	153215	-4.28e-01	6.69e-01
	PTV burden	Depression	Tian, 2024	10800	256930	-3.59e-01	4.55e-01
	PTV burden	Long sleep	Genebass	10225	39517	-4.75e-03	4.56e-01
	PTV burden	Insomnia	All by all	8175	149948	-3.20e-01	7.49e-01
	PTV burden	Autism	ASC	5556	8809		8.40e-01
	PTV burden	Attention-deficit hyperactivity disorders	All by all	3098	167976	-8.02e-01	4.23e-01
	PTV burden	Suicide attempt	Genebass	2830	2489	-1.32e-02	3.78e-01
	PTV burden	Posttraumatic stress disorder	All by all	2806	164364	1.07e+00	2.85e-01
	PTV burden	Parkinson's	Genebass	1901	392940	3.51e-03	7.90e-01
	PTV burden	Alzheimer's	Genebass	900	393941	-1.18e-02	5.38e-01
	PTV burden	Eating disorders	Genebass	681	212932	-2.82e-02	2.05e-01
	PTV burden	Obsessive-compulsive disorders	Genebass	660	394181	-1.98e-03	9.26e-01
F508del GWAS	rs113827944	Neuroticism	Nagel, 2018*	390278		3.32e-04	9.68e-01
	rs113827944	Worry	Nagel, 2018	348219		1.09e-02	2.42e-01
	F508del	Antidepressant use	Levey, 2025	191800	586152	-4.39e-02	3.72e-01
	rs113827944	PTSD	Nievergelt, 2024	137136	1086146	3.77e-03	5.90e-01
	F508del	Alcohol use disorder	Zhou, 2023	113325	639923	2.52e-03	9.31e-01
	F508del	Insomnia	Watanabe, 2022	109548	277440	-1.21e+00	2.27e-01
	rs113827944	Alzheimer's	Wightman, 2021	86531	676386	2.13e-03	7.74e-01
	rs113827944	Schizophrenia	Trubetskoy, 2022	53386	77258	-2.46e-02	4.96e-01
	F508del	Short sleep	Austin-Zimmerman, 2023	47054	382950	-5.80e-03	8.54e-01
	F508del	Cannabis use disorder	Levey, 2023	42281	843744	4.55e-02	7.72e-01
	rs113827944	ADHD	Demontis, 2023	38691	186843	-3.98e-02	3.08e-01
	rs113827944	OCS	Strom, 2024	33942		-9.90e-03	7.74e-01
	rs113827944	Suicide attempt	Dochetry, 2023	31094	758690	2.08e-02	5.80e-01
	F508del	Autism	Grove, 2019	18381	27969	1.00e-01	1.10e-01
	F508del	Anorexia nervosa	Watson, 2019	16992	55525	-2.06e-02	7.37e-01
	F508del	Anxiety	Neale, 2018	16730	101021	1.26e-02	2.59e-02
	F508del	Long sleep	Austin-Zimmerman, 2023	15962	382950	4.29e-02	3.95e-01
	rs113827944	Opioid use disorder	Deak, 2022	15251	538935	7.95e-02	2.42e-03
	rs113827944	Parkinson's	Nalls, 2019	15056	12637	-4.72e-02	6.71e-01

	F508del	Bipolar disorder	BipEx	14210	14422	3.37e-02	6.39e-01
	rs113827944	Tourette	Yu, 2018	4819	9488	-1.84e-01	4.95e-02
	rs113827944	OCD	Arnold, 2018	2688	7037	-3.93e-02	7.39e-01
	rs113827944	Panic disorder	Forstner, 2021	2248	7992	1.93e-02	9.01e-01
	rs10255092	Neuroticism	Nagel, 2018*	390278		4.79e-03	6.28e-02
rs10255092 GWAS	rs10255092	Worry	Nagel, 2018	348219		-7.10e-03	8.58e-03
	rs10255092	Antidepressant use	Levey, 2025	191800	586152	7.30e-03	1.30e-01
	rs10255092	PTSD	Nievergelt, 2024	137136	1086146	9.80e-04	6.15e-01
	rs10255092	Alcohol use disorder	Zhou, 2023	113325	639923	2.32e-03	3.84e-01
	rs10255092	Insomnia	Watanabe, 2022	109548	277440	-1.21e+00	2.27e-01
	rs10255092	Alzheimer's	Wightman, 2021	86531	676386	2.65e-04	8.79e-01
	rs10255092	Bipolar disorder	O'Connell, 2025	59287	781022	-8.00e-04	9.20e-01
	rs10255092	Schizophrenia	Trubetskoy, 2022	53386	77258	-2.01e-02	3.57e-02
	rs10255092	Short sleep	Austin-Zimmerman, 2023	47054	382950	7.20e-03	3.71e-01
	rs10255092	Cannabis use disorder	Levey, 2023	42281	843744	2.50e-03	7.97e-01
	rs10255092	ADHD	Demontis, 2023	38691	186843	-4.70e-03	6.48e-01
	rs10255092	OCS	Strom, 2024	33942		4.30e-03	6.18e-01
	rs10255092	Suicide attempt	Dochetry, 2023	31094	758690	-8.40e-03	3.90e-01
	rs10255092	Autism	Grove, 2019	18381	27969	7.30e-03	6.33e-01
	rs10255092	Anorexia nervosa	Watson, 2019	16992	55525	1.74e-02	2.73e-01
	rs10255092	Anxiety	Neale, 2018	16730	101021	1.79e-03	2.69e-01
	rs10255092	Long sleep	Austin-Zimmerman, 2023	15962	382950	1.41e-02	2.86e-01
	rs10255092	Opioid use disorder	Deak, 2022	15251	538935	-1.23e-03	8.47e-01
	rs10255092	Parkinson's	Nalls, 2019	15056	12637	-2.96e-02	2.02e-01
	rs10255092	Tourette	Yu, 2018	4819	9488	3.24e-02	2.69e-01
	rs10255092	OCD	Arnold, 2018	2688	7037	3.58e-02	3.44e-01
	rs10255092	Panic disorder	Forstner, 2021	2248	7992	6.30e-03	8.72e-01

* Results obtained from the NDKP browser (https://ndkp.hugeamp.org/, accessed Sep 19th, 2025)

Supplemental Appendix References

1. Genebass [Internet]. [cited 2025 Oct 2]. Available from: https://app.genebass.org/

2. All by All [Internet]. [cited 2025 Oct 2]. Available from: https://allbyall.researchallofus.org/

3. FinnGen R12 + UKBB browser [Internet]. [cited 2025 Oct 13]. Available from: https://metaresults-ukbb.finngen.fi/

4. SCHEMA browser [Internet]. [cited 2025 Oct 2]. Available from: https://schema.broadinstitute.org/gene/ENSG00000001626

5. Autism Sequencing Consortium exome analysis browser [Internet]. [cited 2025 Oct 2]. Available from: https://asc.broadinstitute.org/gene/ENSG00000001626

6. Bipolar Exomes Browser [Internet]. [cited 2025 Oct 2]. Available from: https://bipex.broadinstitute.org/gene/ENSG00000001626

7. Tian R, Ge T, Kweon H, Rocha DB, Lam M, Liu JZ, et al. Whole-exome sequencing in UK Biobank reveals rare genetic architecture for depression. Nat Commun. 2024;15(1):1755.

8. Deak JD, Zhou H, Galimberti M, Levey DF, Wendt FR, Sanchez-Roige S, et al. Genome-wide association study in individuals of European and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant risk loci. Mol Psychiatry. 2022;27(10):3970–9.

9. Neale UK Biobank GWAS round 2 [Internet]. [cited 2025 Oct 1]. Available from: https://www.nealelab.is/uk-biobank

10. Yu D, Sul JH, Tsetsos F, Nawaz MS, Huang AY, Zelaya I, et al. Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. American Journal of Psychiatry. 2019;176(3):217–27.

11. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. Nature genetics. 2019;

12. Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, Agee M, et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. Nat Genet. 2022;54(8):1125–32.

13. Nagel M, Jansen PR, Stringer S, Watanabe K, Leeuw CA de, Bryois J, et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. Nat Genet. 2018;50(7):920–7.

14. Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, Nielsen TT, et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nat Genet. 2023;55(2):198–208.

15. Levey D, Galimberti M, Deak J, Gupta P, Empke SLL, Adhikari K, et al. Genetics of SSRI antidepressant use and relationship to psychiatric and medical traits. Hum Genet Genom Adv. 2026;7(1):100500.

16. Austin-Zimmerman I, Levey DF, Giannakopoulou O, Deak JD, Galimberti M, Adhikari K, et al. Genome-wide association studies and cross-population meta-analyses investigating short and long sleep duration. Nat Commun. 2023;14(1):6059.

19. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604(7906):502–8.

20. Docherty AR, Mullins N, Ashley-Koch AE, Qin X, Coleman JRI, Shabalin A, et al. GWAS Meta-Analysis of Suicide Attempt: Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific Health Factors. Am J Psychiatry. 2023;180(10):723–38.

21. Nievergelt CM, Maihofer AX, Atkinson EG, Chen CY, Choi KW, Coleman JRI, et al. Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder. Nat Genet. 2024;56(5):792–808.

22. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet Neurology. 2019;18(12):1091–102.

23. Initiative ANG, Consortium EDWG of the PG, Watson HJ, Yilmaz Z, Thornton LM, Hübel C, et al. Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. Nat Genet. 2019;51(8):1207–14.

24. Arnold PD, Askland KD, Barlassina C, Bellodi L, Bienvenu OJ, Black D, et al. Revealing the complex genetic architecture of obsessive–compulsive disorder using meta-analysis. Mol Psychiatry. 2018;23(5):1181–8.

25. Levey DF, Galimberti M, Deak JD, Wendt FR, Bhattacharya A, Koller D, et al. Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implications. Nat Genet. 2023;55(12):2094–103.

26. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet. 2021;53(9):1276–82.

27. Strom NI, Gerring ZF, Galimberti M, Yu D, Halvorsen MW, Abdellaoui A, et al. Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorder. Nat Genet. 2025;57(6):1389–401.

28. Forstner AJ, Awasthi S, Wolf C, Maron E, Erhardt A, Czamara D, et al. Genome-wide association study of panic disorder reveals genetic overlap with neuroticism and depression. Mol Psychiatry. 2021;26(8):4179–90.

29. Zhou H, Kember RL, Deak JD, Xu H, Toikumo S, Yuan K, et al. Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals. Nat Med. 2023;29(12):3184–92.

29. O'Connell KS, Koromina M, Veen T van der, Boltz T, David FS, Yang JMK, et al. Genomics yields biological and phenotypic insights into bipolar disorder. Nature. 2025;639(8056):968–75.

US


Depression
Proportion (95% CI),%
60
40
20
0
14.7
17.0
19.4
21.1
23.9
25.1
27.7
29.0
30.1
Year -5
Year -4
Year -3
Year -2
Year -1
Year 1
Year 2
Year 3
Year 4


Anxiety
Proportion (95% CI),%
60
40
20
0
9.5
12.4
16.3
18.8
21.6
23.9
27.5
29.8
31.1
Year -5
Year -4
Year -3
Year -2
Year -1
Year 1
Year 2
Year 3
Year 4

Germany


Depression
Proportion (95% CI),%
60
40
20
0
N/A
5.1
4.0
4.2
5.6
5.8
6.0
6.3
7.9
Year -5
Year -4
Year -3
Year -2
Year -1
Year 1
Year 2
Year 3
Year 4


Anxiety
Proportion (95% CI),%
60
40
20
0
N/A
N/A
N/A
N/A
N/A
4.0
4.6
4.6
4.9
Year -5
Year -4
Year -3
Year -2
Year -1
Year 1
Year 2
Year 3
Year 4

CFTR protein-truncating variants associations



F508del -CFTR associations



Figure E1. PRISMA flow diagram